GLP-1 medications
GLP-1 is a hormone your gut releases after you eat — it tells your brain you're full and helps your body manage blood sugar. GLP-1 medications (semaglutide, tirzepatide, and newer molecules) copy that signal, which is why they're so widely studied for weight management and metabolic health.
The articles below explain how these medications work, what the research actually shows, and what side effects and dosing schedules look like in practice. Promise offers compounded GLP-1 medications by prescription only: a licensed provider reviews every request, and not everyone qualifies.
331 articles on this topic
-

Tirzepatide for Fatty Liver: What the Trials Show
In a phase 2 trial, liver inflammation cleared in up to 62% of people on tirzepatide versus 10% on placebo. It is still not approved for any liver disease, and the phase 3 answer is years away.
-

When Did the Tirzepatide Shortage End? The Dates
The FDA took tirzepatide off its shortage list on October 2, 2024. A lawsuit, a second decision and two grace periods followed. Here is the timeline, read from the FDA's own documents, and what it means for a prescription today.
-

Flu Shot on Semaglutide: Yes, and When to Get It
Semaglutide and tirzepatide labels list no vaccine interaction. CDC's flu guidance continues vaccination after October while flu is circulating.
-

Semaglutide and Blood Pressure: How Much It Drops
In the main weight-loss trial, the top number fell about 5 points more on semaglutide than on placebo, mostly riding on weight loss. Here is what that gap looks like, who sees more of it, and when a falling reading needs a second look.
-

SURMOUNT-4 Results: What Stopping Tirzepatide Did
SURMOUNT-4 gave adults tirzepatide for 36 weeks, then switched half of them, by chance, to a look-alike placebo. Over the next year the placebo group regained much of its loss while the other half kept losing, and who made it to that switch shapes what the trial can tell you.
-

Tirzepatide and Pregnancy: What the Evidence Says
Tirzepatide is stopped once a pregnancy is recognized, and the U.S. labels set no fixed wait before trying to conceive. Europe and the UK use at least one month, and human data specific to tirzepatide are still thin.
-

California GLP-1 Law: No Immediate Discount
SB 1089 gives California a path to negotiate lower GLP-1 costs. It does not fund a launch, set a patient price or restore Medi-Cal weight-loss coverage.
-

Why Do People Stop Taking GLP-1? Cost Matters
A new semaglutide study links higher patient costs with poorer adherence. The recurring bill deserves a conversation before the first shipment.
-

GLP-1 for Overweight BMI 25: A Case for Trials
A September study found raised heart risk in many adults with BMI 25–26.9. It makes a case for treatment trials, without changing who qualifies today.
-

GLP-1 Nutritional Deficiencies—Children Need Care
A September study found nutrient-deficiency or related-complication diagnoses in about 1 in 6 young GLP-1 patients within a year. The finding highlights early nutrition care, without proving the medicines caused those problems.
-

GLP-1 Without Diabetes or Obesity: Use Is Rising
A September study found more than 1.1 million GLP-1 recipients without documented eligibility. It raises questions about screening and evidence, without judging every prescription.
-

Ozempic Vision Loss Lawsuit: What the Cases Mean
The federal vision-loss cases are pending, and current eye-safety guidance calls for individual treatment decisions. For sudden vision loss, contact your healthcare professional right away and seek urgent care.
-

Ribupatide Trials Full; Results Expected in 2028
Kailera has finished recruiting for three global ribupatide trials. Results are expected in mid-2028; the drug remains experimental today.
-

Semaglutide Pancreatic Cancer Study: No Increase
New Nordic findings are reassuring for adults with type 2 diabetes. Short follow-up and excluded medical histories leave important questions open.
-

Survodutide Results: Weight Loss and 18% Dropout
The new diabetes trial reported up to 13.1% average weight loss assuming continued treatment, and 9.8% when counting treatment stops. Stomach and bowel side effects led 18% to stop.
-

What Is a Drug Half-Life? A Plain-English Guide
Half-life is how long it takes the level of a medicine in your blood to fall by half. It explains weekly shots, peptides that clear in minutes, and why a new dose takes weeks to settle.
-

Ozempic Prescribing Information, Explained
The Ozempic injection label, revised May 2026, covers three type 2 diabetes uses, a 0.25 mg to 2 mg dose ladder, the thyroid boxed warning, side-effect rates and storage. Here it is in plain words.
-

CagriSema Food Noise: Fewer Cravings in a Trial
A 130-person trial reported fewer cravings and changed brain responses to food pictures. The scans add evidence, with limits that matter.
-

Counterfeit Ozempic Charges: What to Check Now
Federal charges describe an alleged counterfeit Ozempic distribution scheme. FDA’s pen warnings and a traceable pharmacy record explain what someone holding a pen can check.
-

Generic Wegovy: New Lawsuit, No U.S. Launch Date
Mylan's September 23 patent challenge sets no U.S. generic launch date. Here's what the filing changes for someone prescribed semaglutide.
Page 7 of 17 · 331 articles